Lymphoma

GO43878(GLOBRYTE)

A PHASE III, OPEN-LABEL, MULTICENTER,;RANDOMIZED STUDY EVALUATING GLOFITAMAB AS;A SINGLE AGENT VERSUS INVESTIGATORÀS CHOICE;IN PATIENTS WITH RELAPSED/REFRACTORY;MANTLE CELL LYMPHOMA.
  • Open at Saint-Cloud since : 16/02/2024
  • Target : Adult
  • Phase : Phase III

Trial description

To evaluate the efficacy of glofitamab monotherapy compared with an investigatorÀs choice of BR or R-Len with respect to PFS;À PFS, defined as the time from randomization to the first occurrence of disease progression or death from any cause, as determined by the BIRC according to Lugano Response Criteria for Malignant Lymphoma (hereafter referred to as the 2014 Lugano Response Criteria).
Url of the trial

Main investigator